What Allogene Therapeutics, Inc. does.

We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.

After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, multiple anticipated clinical readouts are expected in the second quarter of 2026. These readouts could begin to validate several key scientific and clinical assumptions underlying off-the-shelf CAR T therapy, including biologic activity, safety, and the feasibility of standardized, readily available cell therapy across oncology and autoimmune indications.

Revenue and profit, by fiscal year.

More on ALLO.

• Allogene Therapeutics, Inc. summary
• Allogene Therapeutics, Inc. financial statements
• Allogene Therapeutics, Inc. key metrics
• Allogene Therapeutics, Inc. health scores and style box
• Allogene Therapeutics, Inc. earnings
• Allogene Therapeutics, Inc. dividends
• Allogene Therapeutics, Inc. valuation
• Allogene Therapeutics, Inc. ownership and insiders
• Allogene Therapeutics, Inc. peers

Figures from Allogene Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.